Anti-malarial Drugs-Europe Market Status and Trend Report 2013-2023
Report Summary
Anti-malarial Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anti-malarial Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Anti-malarial Drugs 2013-2017, and development forecast 2018-2023
Main market players of Anti-malarial Drugs in Europe, with company and product introduction, position in the Anti-malarial Drugs market
Market status and development trend of Anti-malarial Drugs by types and applications
Cost and profit status of Anti-malarial Drugs, and marketing status
Market growth drivers and challenges
The report segments the Europe Anti-malarial Drugs market as:
Europe Anti-malarial Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Anti-malarial Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Quinine
Chloroquine
Pyrimethamine
Amodiaquine
Proguanil
Mefloquine
Sulfonamide
Other
Europe Anti-malarial Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Falciparum Malaria
Vivax Malaria
Others
Europe Anti-malarial Drugs Market: Players Segment Analysis (Company and Product introduction, Anti-malarial Drugs Sales Volume, Revenue, Price and Gross Margin):
Merck KGaA
F. Hoffmann-La Roche AG
Novartis AG
GlaxoSmithKline Plc
Ranbaxy Laboratories
Zydus Cadila
Alvizia Health Care
Bayer AG
Pfizer, Inc.
Ipca Laboratories Ltd
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Anti-malarial Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anti-malarial Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Anti-malarial Drugs 2013-2017, and development forecast 2018-2023
Main market players of Anti-malarial Drugs in Europe, with company and product introduction, position in the Anti-malarial Drugs market
Market status and development trend of Anti-malarial Drugs by types and applications
Cost and profit status of Anti-malarial Drugs, and marketing status
Market growth drivers and challenges
The report segments the Europe Anti-malarial Drugs market as:
Europe Anti-malarial Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Anti-malarial Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Quinine
Chloroquine
Pyrimethamine
Amodiaquine
Proguanil
Mefloquine
Sulfonamide
Other
Europe Anti-malarial Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Falciparum Malaria
Vivax Malaria
Others
Europe Anti-malarial Drugs Market: Players Segment Analysis (Company and Product introduction, Anti-malarial Drugs Sales Volume, Revenue, Price and Gross Margin):
Merck KGaA
F. Hoffmann-La Roche AG
Novartis AG
GlaxoSmithKline Plc
Ranbaxy Laboratories
Zydus Cadila
Alvizia Health Care
Bayer AG
Pfizer, Inc.
Ipca Laboratories Ltd
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF ANTI-MALARIAL DRUGS
1.1 Definition of Anti-malarial Drugs in This Report
1.2 Commercial Types of Anti-malarial Drugs
1.2.1 Quinine
1.2.2 Chloroquine
1.2.3 Pyrimethamine
1.2.4 Amodiaquine
1.2.5 Proguanil
1.2.6 Mefloquine
1.2.7 Sulfonamide
1.2.8 Other
1.3 Downstream Application of Anti-malarial Drugs
1.3.1 Falciparum Malaria
1.3.2 Vivax Malaria
1.3.3 Others
1.4 Development History of Anti-malarial Drugs
1.5 Market Status and Trend of Anti-malarial Drugs 2013-2023
1.5.1 Europe Anti-malarial Drugs Market Status and Trend 2013-2023
1.5.2 Regional Anti-malarial Drugs Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Anti-malarial Drugs in Europe 2013-2017
2.2 Consumption Market of Anti-malarial Drugs in Europe by Regions
2.2.1 Consumption Volume of Anti-malarial Drugs in Europe by Regions
2.2.2 Revenue of Anti-malarial Drugs in Europe by Regions
2.3 Market Analysis of Anti-malarial Drugs in Europe by Regions
2.3.1 Market Analysis of Anti-malarial Drugs in Germany 2013-2017
2.3.2 Market Analysis of Anti-malarial Drugs in United Kingdom 2013-2017
2.3.3 Market Analysis of Anti-malarial Drugs in France 2013-2017
2.3.4 Market Analysis of Anti-malarial Drugs in Italy 2013-2017
2.3.5 Market Analysis of Anti-malarial Drugs in Spain 2013-2017
2.3.6 Market Analysis of Anti-malarial Drugs in Benelux 2013-2017
2.3.7 Market Analysis of Anti-malarial Drugs in Russia 2013-2017
2.4 Market Development Forecast of Anti-malarial Drugs in Europe 2018-2023
2.4.1 Market Development Forecast of Anti-malarial Drugs in Europe 2018-2023
2.4.2 Market Development Forecast of Anti-malarial Drugs by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Anti-malarial Drugs in Europe by Types
3.1.2 Revenue of Anti-malarial Drugs in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Anti-malarial Drugs in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Anti-malarial Drugs in Europe by Downstream Industry
4.2 Demand Volume of Anti-malarial Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Anti-malarial Drugs by Downstream Industry in Germany
4.2.2 Demand Volume of Anti-malarial Drugs by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Anti-malarial Drugs by Downstream Industry in France
4.2.4 Demand Volume of Anti-malarial Drugs by Downstream Industry in Italy
4.2.5 Demand Volume of Anti-malarial Drugs by Downstream Industry in Spain
4.2.6 Demand Volume of Anti-malarial Drugs by Downstream Industry in Benelux
4.2.7 Demand Volume of Anti-malarial Drugs by Downstream Industry in Russia
4.3 Market Forecast of Anti-malarial Drugs in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTI-MALARIAL DRUGS
5.1 Europe Economy Situation and Trend Overview
5.2 Anti-malarial Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 ANTI-MALARIAL DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Anti-malarial Drugs in Europe by Major Players
6.2 Revenue of Anti-malarial Drugs in Europe by Major Players
6.3 Basic Information of Anti-malarial Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Anti-malarial Drugs Major Players
6.3.2 Employees and Revenue Level of Anti-malarial Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANTI-MALARIAL DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Merck KGaA
7.1.1 Company profile
7.1.2 Representative Anti-malarial Drugs Product
7.1.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Merck KGaA
7.2 F. Hoffmann-La Roche AG
7.2.1 Company profile
7.2.2 Representative Anti-malarial Drugs Product
7.2.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche AG
7.3 Novartis AG
7.3.1 Company profile
7.3.2 Representative Anti-malarial Drugs Product
7.3.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Novartis AG
7.4 GlaxoSmithKline Plc
7.4.1 Company profile
7.4.2 Representative Anti-malarial Drugs Product
7.4.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline Plc
7.5 Ranbaxy Laboratories
7.5.1 Company profile
7.5.2 Representative Anti-malarial Drugs Product
7.5.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Ranbaxy Laboratories
7.6 Zydus Cadila
7.6.1 Company profile
7.6.2 Representative Anti-malarial Drugs Product
7.6.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Zydus Cadila
7.7 Alvizia Health Care
7.7.1 Company profile
7.7.2 Representative Anti-malarial Drugs Product
7.7.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Alvizia Health Care
7.8 Bayer AG
7.8.1 Company profile
7.8.2 Representative Anti-malarial Drugs Product
7.8.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Bayer AG
7.9 Pfizer, Inc.
7.9.1 Company profile
7.9.2 Representative Anti-malarial Drugs Product
7.9.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Pfizer, Inc.
7.10 Ipca Laboratories Ltd
7.10.1 Company profile
7.10.2 Representative Anti-malarial Drugs Product
7.10.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Ipca Laboratories Ltd
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI-MALARIAL DRUGS
8.1 Industry Chain of Anti-malarial Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTI-MALARIAL DRUGS
9.1 Cost Structure Analysis of Anti-malarial Drugs
9.2 Raw Materials Cost Analysis of Anti-malarial Drugs
9.3 Labor Cost Analysis of Anti-malarial Drugs
9.4 Manufacturing Expenses Analysis of Anti-malarial Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTI-MALARIAL DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Anti-malarial Drugs in This Report
1.2 Commercial Types of Anti-malarial Drugs
1.2.1 Quinine
1.2.2 Chloroquine
1.2.3 Pyrimethamine
1.2.4 Amodiaquine
1.2.5 Proguanil
1.2.6 Mefloquine
1.2.7 Sulfonamide
1.2.8 Other
1.3 Downstream Application of Anti-malarial Drugs
1.3.1 Falciparum Malaria
1.3.2 Vivax Malaria
1.3.3 Others
1.4 Development History of Anti-malarial Drugs
1.5 Market Status and Trend of Anti-malarial Drugs 2013-2023
1.5.1 Europe Anti-malarial Drugs Market Status and Trend 2013-2023
1.5.2 Regional Anti-malarial Drugs Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Anti-malarial Drugs in Europe 2013-2017
2.2 Consumption Market of Anti-malarial Drugs in Europe by Regions
2.2.1 Consumption Volume of Anti-malarial Drugs in Europe by Regions
2.2.2 Revenue of Anti-malarial Drugs in Europe by Regions
2.3 Market Analysis of Anti-malarial Drugs in Europe by Regions
2.3.1 Market Analysis of Anti-malarial Drugs in Germany 2013-2017
2.3.2 Market Analysis of Anti-malarial Drugs in United Kingdom 2013-2017
2.3.3 Market Analysis of Anti-malarial Drugs in France 2013-2017
2.3.4 Market Analysis of Anti-malarial Drugs in Italy 2013-2017
2.3.5 Market Analysis of Anti-malarial Drugs in Spain 2013-2017
2.3.6 Market Analysis of Anti-malarial Drugs in Benelux 2013-2017
2.3.7 Market Analysis of Anti-malarial Drugs in Russia 2013-2017
2.4 Market Development Forecast of Anti-malarial Drugs in Europe 2018-2023
2.4.1 Market Development Forecast of Anti-malarial Drugs in Europe 2018-2023
2.4.2 Market Development Forecast of Anti-malarial Drugs by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Anti-malarial Drugs in Europe by Types
3.1.2 Revenue of Anti-malarial Drugs in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Anti-malarial Drugs in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Anti-malarial Drugs in Europe by Downstream Industry
4.2 Demand Volume of Anti-malarial Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Anti-malarial Drugs by Downstream Industry in Germany
4.2.2 Demand Volume of Anti-malarial Drugs by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Anti-malarial Drugs by Downstream Industry in France
4.2.4 Demand Volume of Anti-malarial Drugs by Downstream Industry in Italy
4.2.5 Demand Volume of Anti-malarial Drugs by Downstream Industry in Spain
4.2.6 Demand Volume of Anti-malarial Drugs by Downstream Industry in Benelux
4.2.7 Demand Volume of Anti-malarial Drugs by Downstream Industry in Russia
4.3 Market Forecast of Anti-malarial Drugs in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTI-MALARIAL DRUGS
5.1 Europe Economy Situation and Trend Overview
5.2 Anti-malarial Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 ANTI-MALARIAL DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Anti-malarial Drugs in Europe by Major Players
6.2 Revenue of Anti-malarial Drugs in Europe by Major Players
6.3 Basic Information of Anti-malarial Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Anti-malarial Drugs Major Players
6.3.2 Employees and Revenue Level of Anti-malarial Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANTI-MALARIAL DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Merck KGaA
7.1.1 Company profile
7.1.2 Representative Anti-malarial Drugs Product
7.1.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Merck KGaA
7.2 F. Hoffmann-La Roche AG
7.2.1 Company profile
7.2.2 Representative Anti-malarial Drugs Product
7.2.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche AG
7.3 Novartis AG
7.3.1 Company profile
7.3.2 Representative Anti-malarial Drugs Product
7.3.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Novartis AG
7.4 GlaxoSmithKline Plc
7.4.1 Company profile
7.4.2 Representative Anti-malarial Drugs Product
7.4.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline Plc
7.5 Ranbaxy Laboratories
7.5.1 Company profile
7.5.2 Representative Anti-malarial Drugs Product
7.5.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Ranbaxy Laboratories
7.6 Zydus Cadila
7.6.1 Company profile
7.6.2 Representative Anti-malarial Drugs Product
7.6.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Zydus Cadila
7.7 Alvizia Health Care
7.7.1 Company profile
7.7.2 Representative Anti-malarial Drugs Product
7.7.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Alvizia Health Care
7.8 Bayer AG
7.8.1 Company profile
7.8.2 Representative Anti-malarial Drugs Product
7.8.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Bayer AG
7.9 Pfizer, Inc.
7.9.1 Company profile
7.9.2 Representative Anti-malarial Drugs Product
7.9.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Pfizer, Inc.
7.10 Ipca Laboratories Ltd
7.10.1 Company profile
7.10.2 Representative Anti-malarial Drugs Product
7.10.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Ipca Laboratories Ltd
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI-MALARIAL DRUGS
8.1 Industry Chain of Anti-malarial Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTI-MALARIAL DRUGS
9.1 Cost Structure Analysis of Anti-malarial Drugs
9.2 Raw Materials Cost Analysis of Anti-malarial Drugs
9.3 Labor Cost Analysis of Anti-malarial Drugs
9.4 Manufacturing Expenses Analysis of Anti-malarial Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTI-MALARIAL DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
